Calculus Capital

Calculus Capital is a pioneer of EIS (Enterprise Investment Scheme) investments, having launched the first UK approved EIS fund in 1999. They have since launched a generalist EIS Fund every year, multiple VCT (Venture Capital Trust) share issues, and a Knowledge Intensive EIS Fund in October 2022. In January 2026, they launched the Calculus Inheritance Tax Solution, providing secured loans for film and TV productions. Their investment strategy focuses on capital appreciation through investments in EIS and VCT qualifying companies, utilizing a diligent investment and monitoring process. They distinguish themselves from other EIS and VCT fund managers through their record of profitable exits. Calculus backs innovators, experts, and game changers across the fastest-growing sectors in the UK. They focus on companies driving innovation, advancing healthcare, and creating jobs and opportunities throughout the country. Their Inheritance Tax Solution invests in companies that provide secured loans to support film and television content production, offering diversification beyond traditional structures. They aim to diversify client portfolios not just by provider, but also by sector, asset behavior, and risk drivers. Calculus has invested in numerous entrepreneurial growth companies across a variety of sectors. Their current portfolio includes investments in companies such as Trogenix, Ensilitech, Booked it, Smartr365, WorkL, Tagomics, Tozaro (formerly MIP Diagnostics), Hinterview, Mo, and Laverock Therapeutics. These companies span industries from biotech and healthcare to software and recruitment. Calculus Capital aims to identify and invest in companies that can contribute to innovation and growth of the UK economy.